US 12,473,584 B2
Method for detecting the presence, identification and quantification in a blood sample of anticoagulants which are blood coagulation enzymes inhibitors, and means for the implementation thereof
Sébastien Kerdelo, Paris (FR)
Assigned to DIAGNOSTICA STAGO, Asnieres-sur-Seine (FR)
Appl. No. 17/311,195
Filed by DIAGNOSTICA STAGO, Asnieres sur Seine (FR)
PCT Filed Dec. 6, 2019, PCT No. PCT/EP2019/084069
§ 371(c)(1), (2) Date Jun. 4, 2021,
PCT Pub. No. WO2020/115315, PCT Pub. Date Jun. 11, 2020.
Claims priority of application No. 1872562 (FR), filed on Dec. 7, 2018.
Prior Publication US 2022/0002779 A1, Jan. 6, 2022
Int. Cl. C12Q 1/56 (2006.01); G16B 40/20 (2019.01)
CPC C12Q 1/56 (2013.01) [G16B 40/20 (2019.02); G01N 2333/745 (2013.01); G01N 2333/96444 (2013.01)] 14 Claims
 
1. An in vitro method for detecting, in a blood sample previously drawn from a subject, the presence of an inhibitor of a blood coagulation enzyme, wherein, prior to performing the method, the presence of any said inhibitor in the subject is unknown, the blood coagulation enzyme being selected, independently, from factor Xa (FXa) and factor IIa (FIIa), the method comprising the following steps:
a) carrying out a competitive enzymatic assay on a blood sample previously drawn from a subject in order to provide, as a result, one or more competitive kinetic measurement(s), either having regard to an inhibitor of factor Xa, or to an inhibitor of factor IIa, then
b) inputting, by a processor, the kinetic measurement(s) obtained in step a) to a classification decision model A obtained from a trained automated supervised learning model, the supervised learning model being selected from: support-vector machines, neural networks and k-nearest neighbour models, then
c) determining, by the processor using the classification decision model A:
(i) the absence of an inhibitor when the use of the model by the processor excludes the presence of an inhibitor, or
(ii) the presence of an inhibitor when the use of the model by the processor confirms the presence of an inhibitor; and
(d) generating, by the processor, an output indicating, as determined in step c), the presence or absence of an inhibitor in the blood sample.